cancel
Showing results for 
Search instead for 
Did you mean: 

BLOG: Lutetium for metastatic castrate resistant prostate cancer (VISION Trial)

Chris_McNamara
Community Manager
Community Manager
0 0 65

Banner_VISION Trial.jpg

 

Lutetium for metastatic castrate resistant prostate cancer (VISION Trial)

Despite recent research advances, metastatic castration-resistant prostate cancer continues to be fatal. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)–PSMA-617 is a radioligand therapy that distributes beta-particle radiation to PSMA-expressing cells and the adjacent microenvironment. It is capable of targeting prostate cancer cells whilst leaving most normal tissues intact in patients who have been chosen with the aid of imaging to confirm radionuclide binding. Research has previously shown that it has been linked to encouraging biochemical and radiographic response rates, reduced toxicity levels and less pain.

An international, open-label, phase 3 trial was undertaken by the VISION Trial Team, evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer (with at least one metastatic lesion on baseline MRI, bone scan or CT) previously treated with at least one androgen-receptor–pathway inhibitor and one or two taxane chemotherapy regimens and who had PSMA-positive gallium-68 (68Ga)–labelled PSMA-11 positron emission tomographic–computed tomographic scans (PET-CT Scan)1. A positive PSMA PET scan was defined as at least one PSMA-positive metastatic lesion and no PSMA-negative lesions. In the protocol, the existence of PSMA-positive lesions was defined as 68Ga-PSMA-11 uptake greater than that of liver parenchyma in one or more metastatic lesions of any size in any organ system. The presence of PSMA-negative lesions was defined in the protocol as PSMA uptake equal to or lower than that of liver parenchyma in any lymph node with a short axis of at least 2.5 cm, in any metastatic solid-organ lesions with a short axis of at least 1.0 cm, or in any metastatic bone lesion with a soft-tissue component of at least 1.0 cm in the short axis. Patients had to attain an Eastern Cooperative Oncology Group (ECOG) performance-status score of <3, life expectancy >6 months and satisfactory organ and bone marrow function.

Patients were randomly assigned in a 2:1 ratio to receive either 177Lu-PSMA-617 (7.4 GBq every 6 weeks for 4-6 cycles) plus protocol-permitted standard care or standard care only. Protocol-permitted standard care excluded immunotherapy, chemotherapy, radium-223 (223Ra), and investigational drugs. Follow-up MRI or CT and technetium-99m (99mTc)–labelled methylene diphosphonate bone scans were scheduled to take place every 8 weeks for 24 weeks and then every 12 weeks after that. Patients received sustained standard care, with or without 177Lu-PSMA-617, until an impermissible level of toxic effects occurred, imaging documented disease progression was noted, a determined lack of clinical benefit was identified, or a proscribed treatment was considered critical. Patients whose condition was deemed to be suitable for additional chemotherapy could terminate the trial treatment and receive chemotherapy at their physician’s discretion. The alternate primary end points were imaging-based progression-free survival and overall survival. Key secondary end points were disease control, objective response, and time to symptomatic skeletal events. Adverse events during treatment were those presenting less than 30 days after the final dose and prior to subsequent anticancer therapy. Health-related quality of life was determined with the aid of the Functional Assessment of Cancer Therapy– Prostate questionnaire and pain evaluated with the use of the Brief Pain Inventory–Short Form.

Between June 2018 and mid-October 2019, a total of 831 of 1179 screened patients underwent randomization. The baseline characteristics of the patients were balanced between the groups. The median follow-up was 20.9 months. 177Lu-PSMA-617 plus standard care significantly prolonged survival, as compared with standard care, both imaging-based progression-free survival (median, 8.7 vs. 3.4 months) and overall survival (median, 15.3 vs. 11.3 months). The prevalence of adverse events of grade 3 or above was greater with 177Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not negatively affected.

The lack of a placebo control and of a double-blind design is a self-reported study limitation. This is owing to the limitations of clinical trials of radiopharmaceuticals in general, due to the challenges related to radiation protection regulations and the ease of detecting radioactivity in the smartphone era.

Radioligand therapy with 177Lu-PSMA-617 is therefore capable of prolonging imaging-based progression-free survival and survival overall when combined with standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. Future studies could determine whether Lutetium can provide therapeutic assistance earlier in the treatment sequence than used in this trial, as compared with alternative treatments.

Reference

Sartor O et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385(12): 1091-1103.

 

Chris_McNamara_0-1622520551637.jpeg

 About the Author

Kalli Spencer

MBBCh, FC Urol (SA), MMed (Urol), Dip.Couns (AIPC)

Kalli is an internationally renowned Urological Surgeon, specialising in oncology and robotic surgery. He trained and worked in South Africa, before relocating to Australia where he has worked at Macquarie University Hospital and Westmead Hospital. His passion for what he does extends beyond the operating room, through public health advocacy, education and community awareness of men’s health, cancer and sexuality.

Kalli has been involved with the Prostate Cancer Foundation of Australia for many years, advocating for improved cancer care and facilitating community prostate cancer support groups.

 

A message from PCFA Chief Operating Officer - Anne Savage

Subject: MSAC application for LuPSMA Imaging & Therapy - We need your help.

Hi Everyone,

We write to seek your support for a submission to Australia’s Medical Services Advisory Committee for Medicare Benefit Schedule listing of 177Lutetium PSMA therapy (here).

The application proposes to:

  1. Independently produce 177LuPSMA in Australia at much lower cost and list the therapy on the Medicare Benefit Schedule.
  2. Provide access to men with mCRPC who have already failed an androgen signalling inhibitor and first line chemotherapy and have progressive or symptomatic disease.
  3. Offer up to six doses of LuPSMA therapy to these men at six-weekly intervals.

To help inform your efforts, we have attached a copy of PCFA’s submission, which includes a summary of evidence and detailed information in support of the application. Please feel free to use this information in your own submissions if you wish to.

There are a few different options for making a submission:

  1. Complete the attached survey and return it to commentsMSAC@health.gov.au.
  2. Send a letter via email to commentsMSAC@health.gov.au.
  3. Simply email your comments to commentsMSAC@health.gov.au.

All of these options are equally valid (the form is harder to use). If you need a hand, please don’t hesitate to call me.

This likelihood of success of this first application for funding of 177LuPSMA is not high, but it won’t stop us from trying.

We close our submission by noting with concern that 33,000 Australian men are certain to die over the next 10 years if no action is taken, and respectfully call on MSAC to respond in their favour. 

It’s hard to find an argument more compelling than that.

We are grateful for your help.

Anne.

**Attached to this blog is the Consultation Survey for PCFA Network Members & the Submission to MSAC on LuPSMA for men with metastatic prostate cancer.

 

Help is Available
 

Prostate Cancer Specialist Telenursing Service:

If your life has been impacted by prostate cancer, our Specialist Telenursing Service is available to help. If you would like to reach out to the PCFA Prostate Cancer Specialist Telenurse Service for any questions you have about your prostate cancer experience, please phone 1800 22 00 99 Monday - Friday 9am - 5pm, Wednesday 10am-8pm (AEST).

 

Prostate Cancer Support Groups:

PCFA is proud to have a national network of affiliated support groups in each state and territory of Australia consisting of men and women who have a passion for assisting others who encounter prostate cancer. This network is made up of over 170 affiliated groups who meet locally to provide one-to-one support, giving a vision of life and hope after treatment. Call us on 1800 22 00 99 to find your local group.

 

MatesCONNECT Telephone-based peer support:

MatesCONNECT is a telephone-based peer support program for men affected by prostate cancer. If you’ve recently been diagnosed with prostate cancer, our MatesCONNECT service can connect you to a trained volunteer who understands what you’re going through. All of our volunteers have been through prostate cancer. Simply call us on 1800 22 00 99 to be connected with a volunteer.

 

Newly diagnosed? or need to find more information -Access the PCFA resources here!

 

House Rules

To help keep this community a welcoming, supportive and caring place we have put together a small list of dos and don'ts for you to think about when posting on our forum, research blog or video gallery. For further information please see our  terms and conditions.

Adhere to PCFA’s five core values of Integrity, Optimism, Compassion, Respect and Commitment.

Our online forum is for you to share experiences with others and does not contain specific medical, counselling or legal advice.  If you require professional advice specific to your individual circumstances we encourage you to see a medical professional, legal professional or counsellor.

No commercial or promotional activity. While members may share information about resources they have found helpful, the PCFA Online Community forum should not be used for the promotion of goods and services. This includes commercial entities passing themselves off as individuals and people who frequently post links to external health professionals or other services.

Be kind to each other - many people using the community are going through a difficult time. A few kind words can go a long way. Please welcome new posters – it can be very nerve-wracking to post on the forum for the first time.

If you or someone you know is suffering from mental health issues, such as depression or anxiety, we encourage you to seek assistance and contact Beyond Blue Tel:1300 224 636 or Lifeline Tel:13 11 14

Speak your mind freely, but please be sensitive to the feelings and experiences of others - you might not always agree, but you can agree to disagree in a peaceful manner.

Don't use offensive language -if a user is found to be using offensive language during their conversations the moderators reserve the right to edit the thread, without warning.

Don't use all capital letters in your posts - it's considered ‘shouting' online and it makes posts difficult to read.

Give each other the benefit of the doubt - please remember that it is all too easy for the tone and meaning of posts to be misinterpreted. Think carefully before replying to a discussion. it It is important to remember that things written rather than said can feel much stronger, so please bear this in mind when reading other people's messages.

Please respect the moderators - their job is to keep the forum safe and constructive so that everybody gets to have his or her fair say.

Stay on topic - try to focus on the original topic. In particular, don't change subject in the middle of an existing thread - just start a new thread.

Read what's already on the forum before posting - you may be repeating what others have already said or asked.

We want PCFA's Online Community to be a secure and helpful environment for all of the community. So please remember that by using PCFA's Online Community you are agreeing to follow our terms and conditions.